Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Etrasimod - Pfizer

Next Previous
Drug Profile

Etrasimod - Pfizer

Alternative Names: APD-334; Etrasimod arginine - Pfizer; Etrasimod L-arginine; PF-07915503; VELSIPITY; Verespiti

Latest Information Update: 30 Oct 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arena Pharmaceuticals
  • Developer Arena Pharmaceuticals; Everest Medicines; Pfizer
  • Class 3-ring heterocyclic compounds; Acetic acids; Amino acids; Anti-inflammatories; Benzene derivatives; Cyclopentanes; Ethers; Fluorinated hydrocarbons; Indoles; Skin disorder therapies; Small molecules
  • Mechanism of Action Sphingosine 1 phosphate receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Eosinophilic oesophagitis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ulcerative colitis
  • Phase II/III Atopic dermatitis
  • Phase II Eosinophilic oesophagitis
  • Discontinued Alopecia areata; Crohn's disease; Inflammatory bowel diseases; Primary biliary cirrhosis; Pyoderma gangrenosum

Most Recent Events

  • 15 Oct 2026 Pfizer completes a phase I trial for pharmacokinetic trial (In volunteers) in Belgium (NCT07153159) (CTIS2025-520930-44-00)
  • 17 Sep 2026 Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) accepts the application for localized manufacturing for Etrasimod and grants Priority Review .
  • 17 Sep 2026 Everest Medicines expects to receive NDA approval for VELSIPITY® etrasimod (VELSIPITY®) tablets in Taiwan, China in the second half of 2026 .

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top